With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.
When vaccines are broadly implemented and SARS-CoV-2 positivity rates are lower, pooled testing may become more widespread as a means to prevent future outbreaks. There may also be greater adoption of serology tests to monitor people who have been vaccinated, as well as the potential for more decentralized testing. Furthermore, clinical labs and test developers will need to adjust for increases in testing volumes for segments that were neglected during the pandemic.
This virtual roundtable discussion will assemble a panel of industry stakeholders, including clinical and public labs, to discuss how they are planning for a post-vaccine testing landscape.
The session will include a live Q&A in which attendees can post questions to our panelists.